Summary
This 8-K filing from Pfizer Inc. (PFE), dated December 11, 2006, primarily serves to provide financial information in a newly adopted XBRL (eXtensible Business Reporting Language) format. The filing includes unaudited financial data from Pfizer's Quarterly Report on Form 10-Q for the quarter ended October 1, 2006, specifically the Condensed Consolidated Statements of Income, Balance Sheets, and Statements of Cash Flows. It is crucial for investors to understand that this filing is part of an SEC voluntary XBRL pilot program. The XBRL data is explicitly stated as unaudited and not the official financial statements. Investors are advised to continue relying on the officially filed versions of financial documents for making investment decisions, as the information presented in this 8-K is for testing technological formats and should not be used for liability purposes under Section 18 of the Exchange Act.
Key Highlights
- 1Pfizer is participating in the SEC's voluntary XBRL pilot program.
- 2The filing furnishes unaudited financial information from Pfizer's Q3 2006 10-Q filing in XBRL format.
- 3Key financial statements included are Income Statements, Balance Sheets, and Cash Flow Statements for relevant periods in 2006 and 2005.
- 4Investors are strongly cautioned that this XBRL data is not the official filing and should not be relied upon for investment decisions.
- 5The XBRL data is for testing the XBRL format and technology, not for official reporting or liability.
- 6Information in this 8-K is not deemed 'filed' for Section 18 of the Exchange Act and has limited liability implications.
- 7The filing includes various XBRL-related documents such as Instance, Schema, Calculation, Label, and Presentation linkbase files.